BDP/FF NEXThaler to Improve Asthma Control Status in the Real World: The NEWTON Study.
asthma
beclometasone dipropionate/formoterol fumarate
dry-powder inhaler
observational study
Journal
Journal of asthma and allergy
ISSN: 1178-6965
Titre abrégé: J Asthma Allergy
Pays: New Zealand
ID NLM: 101543450
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
06
2023
accepted:
18
09
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
In this article, we discuss the importance of real-world data in the treatment of patients with asthma and specifically the role of maintenance and reliever therapy (MART) with beclometasone dipropionate (BDP)/formoterol fumarate dihydrate (FF) delivered through a dry-powder inhaler (DPI) that contains an extrafine formulation. We also present the design of the NEWTON study. This multinational, multicenter, prospective, observational study will evaluate the real-world use of extrafine BDP/FF via a DPI as maintenance therapy and MART in patients with moderate to severe asthma. The study's primary outcome will be the proportion of patients improving their asthma control. Digitally collected patient-reported outcomes, such as the 5-item Asthma Control Questionnaire, the EuroQol 5-dimension 5-level, and the Test of the Adherence to Inhalers, will be used to assess the patient's asthma control, quality of life, and treatment adherence. Moreover, a new patient-reported outcome, the "Speed of change in health feeling" questionnaire, will be validated in a subgroup of patients. Overall, the results of this study will provide a real-life assessment of patients who perceived clinical benefits in a large cohort of asthmatics in Europe treated as per current clinical practice.
Identifiants
pubmed: 37904878
doi: 10.2147/JAA.S422832
pii: 422832
pmc: PMC10613424
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1177-1186Informations de copyright
© 2023 Braido et al.
Déclaration de conflit d'intérêts
AP, EI, and LC are employees of Chiesi Italia S.p.A. SB is an employee of Chiesi Farmaceutici S.p.A. The authors report no other conflicts of interest in this work.
Références
Ther Clin Risk Manag. 2022 Oct 01;18:965-979
pubmed: 36212050
Br J Clin Pharmacol. 2019 Apr;85(4):729-736
pubmed: 30586199
Patient Prefer Adherence. 2020 Oct 07;14:1811-1822
pubmed: 33116426
Asthma Res Pract. 2017 Jan 6;3:1
pubmed: 28078100
Lancet Respir Med. 2013 Mar;1(1):23-31
pubmed: 24321801
Patient Relat Outcome Meas. 2012;3:71-8
pubmed: 23185124
Pneumologie. 2009 Dec;63 Suppl 2:S102-6
pubmed: 20013538
Eur J Pharm Sci. 2023 Apr 1;183:106385
pubmed: 36646153
Pulm Pharmacol Ther. 2022 Dec;77:102169
pubmed: 36252915
Respir Med. 2012 Feb;106(2):205-14
pubmed: 22035853
JAMA. 2018 Apr 10;319(14):1485-1496
pubmed: 29554195
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
BMC Pulm Med. 2011 Jul 15;11:40
pubmed: 21762500
BMC Pulm Med. 2020 Aug 20;20(1):222
pubmed: 32819337
Respir Res. 2012 Dec 06;13:112
pubmed: 23216798
J Asthma Allergy. 2022 Jul 08;15:919-933
pubmed: 35836969
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005533
pubmed: 20393943
Expert Opin Drug Deliv. 2014 Sep;11(9):1497-506
pubmed: 24921434
J Pers Med. 2022 Jan 22;12(2):
pubmed: 35207635
JAMA. 2020 Dec 8;324(22):2301-2317
pubmed: 33270095
Pulm Pharmacol Ther. 2015 Feb;30:121-7
pubmed: 25088067
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
Postepy Dermatol Alergol. 2023 Feb;40(1):16-21
pubmed: 36909914
Multidiscip Respir Med. 2020 Aug 05;15(1):649
pubmed: 32983452
Br J Clin Pharmacol. 2022 Jul;88(7):3016-3022
pubmed: 34719810
J Aerosol Med Pulm Drug Deliv. 2014 Oct;27(5):363-70
pubmed: 24299501
Respir Med. 2009 Jan;103(1):41-9
pubmed: 18977646
Int J Pharm X. 2023 Feb 04;5:100167
pubmed: 36824288
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44
pubmed: 15256389
World Allergy Organ J. 2016 Oct 28;9(1):37
pubmed: 27800118
J Aerosol Med Pulm Drug Deliv. 2021 Sep;34(5):280-292
pubmed: 33944614
Lancet Glob Health. 2023 Feb;11(2):e218-e228
pubmed: 36669806
BMC Pulm Med. 2021 Feb 25;21(1):65
pubmed: 33632183
J Aerosol Med Pulm Drug Deliv. 2018 Oct;31(5):269-280
pubmed: 29989511
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741503